title: Myocyte-specific enhancer factor 2C: a novel target gene of miR-214-3p in suppressing angiotensin II-induced cardiomyocyte hypertrophy.
abstract: The role of microRNA-214-3p (miR-214-3p) in cardiac hypertrophy was not well illustrated. The present study aimed to investigate the expression and potential target of miR-214-3p in angiotensin II (Ang-II)-induced mouse cardiac hypertrophy. In mice with either Ang-II infusion or transverse aortic constriction (TAC) model, miR-214-3p expression was markedly decreased in the hypertrophic myocardium. Down-regulation of miR-214-3p was observed in the myocardium of patients with cardiac hypertrophy. Expression of miR-214-3p was upregulated in Ang-II-induced hypertrophic neonatal mouse ventricular cardiomyocytes. Cardiac hypertrophy was attenuated in Ang-II-infused mice by tail vein injection of miR-214-3p. Moreover, miR-214-3p inhibited the expression of atrial natriuretic peptide (ANP) and β-myosin heavy chain (MHC) in Ang-II-treated mouse cardiomyocytes in vitro. Myocyte-specific enhancer factor 2C (MEF2C), which was increased in Ang-II-induced hypertrophic mouse myocardium and cardiomyocytes, was identified as a target gene of miR-214-3p. Functionally, miR-214-3p mimic, consistent with MEF2C siRNA, inhibited cell size increase and protein expression of ANP and β-MHC in Ang-II-treated mouse cardiomyocytes. The NF-κB signal pathway was verified to mediate Ang-II-induced miR-214-3p expression in cardiomyocytes. Taken together, our results revealed that MEF2C is a novel target of miR-214-3p, and attenuation of miR-214-3p expression may contribute to MEF2Cexpressionin cardiac hypertrophy.
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.|Southern Medical University, Guangzhou 510515, China.
authors: Chun-Mei
authors: CM
authors: Tang
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Fang-Zhou
authors: FZ
authors: Liu
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Jie-Ning
authors: JN
authors: Zhu
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Yong-Heng
authors: YH
authors: Fu
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Qiu-Xiong
authors: QX
authors: Lin
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Chun-Yu
authors: CY
authors: Deng
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.|Southern Medical University, Guangzhou 510515, China.
authors: Zhi-Qin
authors: ZQ
authors: Hu
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Hui
authors: H
authors: Yang
authors: The Libin Cardiovascular Institute of Alberta, Department of Biochemistry &Molecular Biology, The University of Calgary, Calgary, T2N 1N4, Alberta, Canada.
authors: Xi-Long
authors: XL
authors: Zheng
authors: Department of Forensic Pathology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
authors: Jian-Ding
authors: JD
authors: Cheng
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Shu-Lin
authors: SL
authors: Wu
authors: Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China.|Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
authors: Zhi-Xin
authors: ZX
authors: Shan
mesh_terms: D000804:Angiotensin II / Q000633:toxicity; D000818:Animals; D000070416:Antagomirs / Q000378:metabolism; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D006332:Cardiomegaly / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D004195:Disease Models, Animal; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D064326:MEF2 Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism; D018995:Myosin Heavy Chains / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D034622:RNA Interference; D015398:Signal Transduction / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000070416:Antagomirs; D064326:MEF2 Transcription Factors; D035683:MicroRNAs; C534781:Mirn214 microRNA, mouse; D016328:NF-kappa B; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D018995:Myosin Heavy Chains